Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

The weeks and months after a baby is born are a critical time for the growth of the heart of premature babies. This is largely because they are faced with major blood flow changes and increased oxygen demands as they transition to the outside environment during a time where they would normally be developing inside their mother.

A lot of research has identified preterm birth (born before 37 weeks gestation) as a risk factor for developing early heart disease, including heart failure. Heart failure is when the heart can’t pump blood around your body as effectively as it should.

Several studies have shown that preterm birth is linked to abnormalities in the structure and function of their heart, yet the extent and evolution of these changes throughout development, from birth to adulthood, are not well defined. However, it’s important that they are defined as one in ten people worldwide are born preterm.

In our latest study, we performed a meta-analysis of data from published studies that compared the heart’s structure and function using echocardiography or cardiovascular magnetic resonance imaging for people born preterm versus those born at term.

Read the full article on The Conversation website, written by Dr Adam Lewandowski, Radcliffe Department of Medicine.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.